Search

Your search keyword '"Vose, Julie M."' showing total 1,904 results

Search Constraints

Start Over You searched for: Author "Vose, Julie M." Remove constraint Author: "Vose, Julie M."
1,904 results on '"Vose, Julie M."'

Search Results

201. Assessment of Time to CAR-T Cell Therapy and Patients’ Outcomes in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Based on Insurance Status (Public Versus Private) and Distance Traveled to Treatment Center

202. Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access (EA) and Commercial out-of-Specification (OOS) Product

208. Molecular diagnosis of Burkitt's lymphoma

209. The Future of Telehealth for Hematology/Oncology Care

210. The Future of Oncology: Supply and Demand for Oncology Services

214. Contributors

215. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement

230. 507 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of Zuma-1 Cohort 6

231. Contributors

233. Integrated profiling of diffuse large B-cell lymphoma with 7q gain

237. Thirty-Five Year Follow-up Analysis of Follicular Lymphoma Patients Treated through the Nebraska Lymphoma Study Group: Prognostic Factor Analysis and Outcomes

238. Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

240. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

241. TCL-233: Angioimmunoblastic T-Cell Lymphoma: Report on 282 Cases from the Prospective International T-Cell Lymphoma Project

243. Assessment of Time to Insurance Approval and Distance Traveled in Patients Treated with CAR T-Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

244. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

247. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21

Catalog

Books, media, physical & digital resources